Bioavailability of indomethacin-saccharin cocrystals. - Wikidata - awgldk - TriplyDB

Bioavailability of indomethacin-saccharin cocrystals.

Bioavailability of indomethacin-saccharin cocrystals.

http://www.wikidata.org/entity/Q42840455

about

Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5 Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats.Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.Multicomponent chemical imaging of pharmaceutical solid dosage forms with broadband CARS microscopy.Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics.Multicomponent Crystal Systems of Known Antimalarial Drug Molecules.Theophylline cocrystals prepared by spray drying: physicochemical properties and aerosolization performance.Thermodynamic and kinetic investigation on the crucial factors affecting adefovir dipivoxil-saccharin cocrystallization.Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs.Sucralose as co-crystal co-former for hydrochlorothiazide: development of oral disintegrating tablets.Cocrystal of Ibuprofen⁻Nicotinamide: Solid-State Characterization and In Vivo Analgesic Activity Evaluation.Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies

P2860

Q36446679-C7871D8B-B344-483C-91EF-9552EDDBE252 Q36666790-A89D26D0-114D-4507-9D75-FC75BB141967 Q37013110-767F59AC-AD12-4575-9EF2-59EC67B87C22 Q37226778-BC27E7D7-A264-48ED-BE95-5BCA4E3EF001 Q37415146-386B0295-E87B-4E79-8620-A7346B31E9EC Q37693295-008E1E42-0474-4579-BA9B-407B68B2DCA5 Q38236638-C2F8863D-A602-45C4-8893-DF79734BCBA8 Q38586521-31755266-9695-47AE-B023-961F6AFAAF96 Q41988067-1EA5E826-AE29-4C01-8A11-37A09DD7A88F Q43582780-4B4FB0A9-A41F-45ED-8068-9804D5EBE07D Q48166645-4884845A-D9A3-4FD7-8D51-48EF46C580D5 Q53783361-2B2CCBA4-C93E-453A-AD16-B8B051AE7924 Q55424195-9D446C07-CA7F-415B-97CC-62B7979C641F Q57162692-9E814420-5405-4993-9457-65B5576FD83B

P2860

Bioavailability of indomethacin-saccharin cocrystals.

http://www.wikidata.org/entity/Q42840455

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Bioavailability of indomethacin-saccharin cocrystals.

@en

Bioavailability of indomethacin-saccharin cocrystals.

@nl

type

label

Bioavailability of indomethacin-saccharin cocrystals.

@en

Bioavailability of indomethacin-saccharin cocrystals.

@nl

prefLabel

Bioavailability of indomethacin-saccharin cocrystals.

@en

Bioavailability of indomethacin-saccharin cocrystals.

@nl

P1433

Q42840455-72DF9C7F-234E-45A5-8FBB-EABD81A785DB

P1476

Q42840455-D14D2CD6-9632-4470-99D2-AFD50A294F79

P2093

Q42840455-079AF4ED-2CFE-4D36-8ABA-08072F6A647B

Q42840455-1ED36A63-5148-4F77-90ED-3EA0216CA854

Q42840455-50D5BDAA-7B3F-4ADA-BDD5-61ED228E8054

Q42840455-BA11A31A-363F-4AC9-A593-8844E1B77F51

Q42840455-F3D5DC99-89E0-4B17-A6FD-309EA301AB83

P2860

Q42840455-044AE718-8873-45ED-AE13-D21A20E13E3D

Q42840455-08192C4D-C01F-4FB5-A3E7-55FE23F5BFCE

Q42840455-0B93186A-9F74-4B63-BA16-683CA7308EB3

Q42840455-35BB454F-1C5B-4443-B279-E89760DFC53B

Q42840455-37AE884D-97AF-4F49-9181-A65F1E834ABE

Q42840455-5E4C4E68-C3C4-4CB6-BA49-6080F0D4CB28

Q42840455-5FB8A604-82F9-49E8-B589-096EC2FC15E7

Q42840455-6D25F391-AFD2-4565-AB59-217D2E10BE39

Q42840455-9B2C1279-3BD4-4955-9ABF-92C986A4F5D5

Q42840455-9F572C93-68D9-41F8-A6E4-E3C2BFDE27BC

P304

Q42840455-DED6EED6-0D32-4524-8B22-300D0EA924A3

P31

Q42840455-4333DACD-373D-438F-BFE3-F775B231B9CD

P356

Q42840455-16C882FC-04F7-441B-8A32-4230C5160C7D

P433

Q42840455-47E0A89B-2EF6-4CEC-A9DB-57B3FAD8FF6E

P478

Q42840455-294DAF68-004F-4AEE-B087-B679D3595080

P50

Q42840455-039920A6-6784-4165-A0DB-294E34BB09B4

Q42840455-33BE9103-AB80-46B9-9602-22419EEBA514

P577

Q42840455-41C9574E-86DA-4E78-82EA-CD9B4CECFE79

P698

Q42840455-E3BDE572-D5EA-433D-B30C-5B02A8347785

P356

J.2042-7158.2010.01189.X

P1433

Journal of Pharmacy and Pharmacology

P1476

Bioavailability of indomethacin-saccharin cocrystals

@en

P2093

Amjad Alhalaweh

http://www.w3.org/2001/XMLSchema#string

Jeong-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Min-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Min-Sook Jung

http://www.w3.org/2001/XMLSchema#string

Wonkyung Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics.

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

Pharmaceutical co-crystals.

High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.

Drug polymorphism and dosage form design: a practical perspective.

Pharmaceutical Cocrystals and Their Physicochemical Properties.

Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.

Pharmaceutical salts.

P304

1560-1568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.2042-7158.2010.01189.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21039541

http://www.w3.org/2001/XMLSchema#string